6-azabicyclo[3.2.1]octane-2,7-dione | 1552322-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 6-azabicyclo[3.2.1]octane-2,7-dione
• 英文别名: 6-Azabicyclo[3.2.1]octane-2,7-dione
• CAS: 1552322-78-7
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: SXUUIKNYCYOWKO-UHFFFAOYSA-N

物化性质

• 沸点：
  386.0±25.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-羰基环己羧酸 、 叔丁醇 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 反应 16.0h， 生成 6-azabicyclo[3.2.1]octane-2,7-dione
  参考文献：
  名称：

  Boc 保护的 1-（3-氧代环烷基）脲通过一步 Curtius 重排：机制和范围

  摘要：

  1-(3-氧代环丁基) 羧酸 ( 4a )一步转化为N -Boc保护的 1-(3-氧代环丁基) 脲 ( 5a )，这是制备代谢型谷氨酸受体 5 激动剂的关键中间体用二苯基磷酰叠氮化物和三乙胺在叔丁醇中处理。该反应的机理涉及原位生成的氨基甲酸叔丁酯与异氰酸酯中间体的亲核加成。该反应适用于其他 1-(3-氧代环烷基)羧酸，但不适用于线性 γ-酮羧酸。

  DOI：

  10.1016/j.tetlet.2013.12.021

文献信息

• BCL6 INHIBITORS AS ANTICANCER AGENTS
  申请人：Cornell University

  公开号：US20160166549A1

  公开（公告）日：2016-06-16

  The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involvedoncogene in diffuse large B-celllymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice.

  本发明提供了一种使用小分子非肽化合物阻断BCL6 BTB结构域的组合物和方法，如本文所述和索要的。BCL6是BTB-POZ（brie a brae，tramtrack，broad complex/pox virus zincfinger）蛋白家族的转录抑制因子。它是生殖中心（GC）B细胞正常发育所必需的，并且也是弥漫性大B细胞淋巴瘤（DLBCLs）中最常涉及的癌基因，GC B细胞中的BCL6的构成表达会导致小鼠DLBCL。
• US9943506B2
  申请人：——

  公开号：US9943506B2

  公开（公告）日：2018-04-17
• [EN] BCL6 INHIBITORS AS ANTICANCER AGENTS<br/>[FR] INHIBITEURS DE BCL6 UTILISABLES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：MELNICK ARI

  公开号：WO2014204859A2

  公开（公告）日：2014-12-24

  The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (bric a brac, tramtrack, broad complex / pox virus zinc finger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice. DLBCLs are aggressive tumors that arise from germinal center (GC) B- cells and are the most common form of non-Hodgkin's lymphomas. BCL6 is required for survival of DLBCL cells and can limit their ability to respond to DNA damaging agents. It is also frequently expressed in follicular lymphomas (FLs), and may be required for survival of these tumors as well. DLBCL and FL collectively constitute ∼60-70% of B-cell lymphomas and the incidence of these tumors has been rising in recent decades.
• Boc-protected 1-(3-oxocycloalkyl)ureas via a one-step Curtius rearrangement: mechanism and scope
  作者：Xianyu Sun、Rachita Rai、Jeffrey R. Deschamps、Alexander D. MacKerell、Alan I. Faden、Fengtian Xue

  DOI：10.1016/j.tetlet.2013.12.021

  日期：2014.1

  urea (5a), a key intermediate for the preparation of agonists of metabotropic glutamate receptor 5, in one-step when treated with diphenyl phosphoryl azide and triethylamine in tert-butanol. The mechanism of the reaction involves a nucleophilic addition of the in situ generated tert-butyl carbamate to the isocyanate intermediate. This reaction is applicable to other 1-(3-oxocycloalkyl) carboxylic acids

  1-(3-氧代环丁基) 羧酸 ( 4a )一步转化为N -Boc保护的 1-(3-氧代环丁基) 脲 ( 5a )，这是制备代谢型谷氨酸受体 5 激动剂的关键中间体用二苯基磷酰叠氮化物和三乙胺在叔丁醇中处理。该反应的机理涉及原位生成的氨基甲酸叔丁酯与异氰酸酯中间体的亲核加成。该反应适用于其他 1-(3-氧代环烷基)羧酸，但不适用于线性 γ-酮羧酸。